Regeneus (ASX:RGS) announced this week that Dr John Chiplin, PhD and Dr Alan Dunton, M.D. have joined its board to support the company’s global growth strategy.
Dr Chiplin is Managing Director of Newstar Ventures and has significant operational, investment and transactions experienced in the international life science and technology industries.
Previously, he’s served as CEO at three publicly-listed software, biotechnology and cancer immunotherapy companies.
Dr Dunton is a senior pharmaceutical and biotechnology industry leader with experience across large pharmaceutical research and development organisations as well as private biotech companies focused on prescriptive treatment and the development and commercialisation of over-the-counter drugs on a global and local scale.
Regeneus’ CEO Leo Lee spoke with Stockhead about the potential impact of the new appointments.
Click the image below to view the complete video interview with Stockhead.